Literature DB >> 4873660

Controlled comparison of tetracycline and furazolidone in cholera.

N F Pierce, J G Banwell, R C Mitra, G J Caranasos, R I Keimowitz, J Thomas, A Mondal.   

Abstract

A controlled comparison of furazolidone and tetracycline in the treatment of cholera indicates that, in either dosage used, furazolidone reduced total stool volume by 50% and duration of diarrhoea by 40%. These results are comparable to those achieved with tetracycline, which was given in presently recommended dosage. Both furazolidone and tetracycline significantly reduced the rate of stool output within 18 to 24 hours of starting antibiotic treatment. Furazolidone was significantly less effective than tetracycline in rapidly and consistently terminating vibrio excretion. One convalescent carrier of cholera vibrios was identified among control patients; none was identified among patients treated with either tetracycline or furazolidone. All Vibrio cholerae strains tested were sensitive to tetracycline and furazolidone, but larger concentrations of the latter were required to achieve inhibition of growth. It is concluded that tetracycline remains the antibiotic of choice in cholera but that furazolidone would be a useful adjunct to cholera therapy when tetracycline is unobtainable or if strains of V. cholerae with clinically significant resistance to tetracycline should be encountered.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4873660      PMCID: PMC1986263          DOI: 10.1136/bmj.3.5613.277

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  DIRECT BACTERIAL HAEMAGGLUTINATION TEST FOR DIFFERENTIATING EL TOR VIBRIOS FROM V. CHOLERAE.

Authors:  D BARUA; A C MUKHERJEE
Journal:  Bull Calcutta Sch Trop Med       Date:  1963-07

2.  TETRACYCLINE IN THE TREATMENT OF CHOLERA.

Authors:  W B GREENOUGH; R S GORDON; I S ROSENBERG; B I DAVIES; A S BENENSON
Journal:  Lancet       Date:  1964-02-15       Impact factor: 79.321

3.  A new method for the differentiation of Vibrio comma and Vibrio El Tor.

Authors:  G K HAN; T S KHIE
Journal:  Am J Hyg       Date:  1963-03

4.  Probable gallbladder infection in convalescent cholera patients.

Authors:  C K Wallace; P N Anderson; G W Lewis; G V Segre; N F Pierce; T C Brown; S N Sanyal; R H Waldman
Journal:  Lancet       Date:  1967-04-22       Impact factor: 79.321

5.  Furazolidone in the treatment of cholera.

Authors:  R N Chaudhuri; K N Neogy; S N Sanyal; R K Gupta; P Manji
Journal:  Lancet       Date:  1968-02-17       Impact factor: 79.321

6.  Tetracycline sensitivity of Vibrio cholerae in Calcutta.

Authors:  G Lewis; S Sanyal
Journal:  Bull Calcutta Sch Trop Med       Date:  1965-04

7.  Amphetamine.

Authors:  H J Roberts
Journal:  Lancet       Date:  1965-10-30       Impact factor: 79.321

8.  Antibiotic therapy of cholera.

Authors:  J Lindenbaum; W B Greenough; M R Islam
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

9.  Detection of Vibrio cholerae biotype El Tor by purging.

Authors:  E J Gangarosa; H Saghari; J Emile; H Siadat
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

  9 in total
  12 in total

1.  Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents.

Authors:  T Yamamoto; G B Nair; M J Albert; C C Parodi; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Double-blind, randomized, controlled clinical trial of norfloxacin for cholera.

Authors:  S K Bhattacharya; M K Bhattacharya; P Dutta; D Dutta; S P De; S N Sikdar; A Maitra; A Dutta; S C Pal
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Citrate can effectively replace bicarbonate in oral rehydration salts for cholera and infantile diarrhoea.

Authors:  M R Islam
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

4.  Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae.

Authors:  C V Sciortino; J A Johnson; A Hamad
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

5.  Effects of doxycycline in actively purging cholera patients: a double-blind clinical trial.

Authors:  M M Rahaman; M A Majid; M R Islam
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  Efficacy of a single dose of furazolidone for treatment of cholera in children.

Authors:  G H Rabbani; T Butler; M Shahrier; R Mazumdar; M R Islam
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Furazolidone in paediatric cholera.

Authors:  A W Karchmer; G T Curlin; M I Huq; N Hirschhorn
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

8.  Gastric acidity in cholera and noncholera diarrhoea.

Authors:  G H Sack; N F Pierce; K N Hennessey; R C Mitra; R B Sack; D N Mazumder
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

Review 9.  Antimicrobial drugs for treating cholera.

Authors:  Ya'ara Leibovici-Weissman; Ami Neuberger; Roni Bitterman; David Sinclair; Mohammed Abdus Salam; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2014-06-19

10.  Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial.

Authors:  G H Rabbani; M R Islam; T Butler; M Shahrier; K Alam
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.